ALK and non-small cell lung carcinoma: For CheckMate 017 (Motzer et al., 2015; Reck et al., 2018) examining the second-line treatment of nivolumab for squamous-cell stage IIIB or IV NSCLC after platinum-based therapy, and KEYNOTE-024 (Herbst et al., 2016; Brahmer et al., 2017) examining the first-line pembrolizumab treatment for stage IV NSCLC with EGFR and ALK wild type, both ASCO-VF scores and ESMO-MCBS grades were high, demonstrating that they were valuable.